Simple Summary Three-dimensional (3D) cell culture models have been proposed as
alternatives for initial drug screening to increase drug development efficiency. In addition to …

No common malignancy is as rapidly and inevitably fatal as pancreatic ductal
adenocarcinoma (PDA). This grim fact has driven substantial research efforts into this …

Background The oligometastatic paradigm suggests that some patients with a limited
number of metastases might be cured if all lesions are eradicated. Evidence from …

Background We evaluated the efficacy and safety of ganitumab (a mAb antagonist of insulin-
like growth factor 1 receptor) or conatumumab (a mAb agonist of human death receptor 5) …

Bayesian Designs for Phase I–II Clinical Trials Page 1 Page 2 Ying Yuan The University of
Texas MD Anderson Cancer Center Houston, Texas, USA Hoang Q. Nguyen The University of …

Purpose: We discuss designs and interpretable metrics of bias and statistical efficiency of
“externally controlled” trials (ECT) and compare ECT performance to randomized and single …

Due the implementation of nanotechnologies in the pharmaceutical industry over the last
few decades, new type of cutting-edge formulations—nanopharmaceutics—have been …

Cancer prognosis remains a lottery dependent on cancer type, disease stage at diagnosis,
and personal genetics. While investment in research is at an all‐time high, new drugs are …

Despite the wide variety of existing therapies, multiple myeloma (MM) remains a disease
with dismal prognosis. Choosing the right treatment for each patient remains one of the …

Simple Summary This review aims at analyzing an emergent topic regarding the possible
combined use of poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi), anticancer drugs …